Pathstone Family Office’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Pathstone Family Office’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$439K	Buy	+5,755	New	+$591K	﹤0.01%	1104

Other funds holding LABU

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Pathstone Family Office's LABU Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q3 2023: 5,755 shares worth $439K. The stake represents ﹤0.01% of the portfolio and ranks #1104 among its holdings.

47 funds tracked by Wall St. Rank hold LABU as of Q3 2023.

Pathstone Family Office held 5,755 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $439K as of Q3 2023.
Direxion Daily S&P Biotech Bull 3X ETF was a new Pathstone Family Office position in Q3 2023.
Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1104 holding.
47 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.